Q3 Earnings Season: Steady Start, But Performance Varies Widely

ECONOMY
Whalesbook Logo
AuthorRiya Kapoor|Published at:
Q3 Earnings Season: Steady Start, But Performance Varies Widely
Overview

India's Q3 FY26 earnings season kicked off with a steady tone, showing robust loan growth from major banks and significant sales gains in retail and real estate. However, results are uneven, with some firms like Dabur India and Trent lagging expectations, while global tariff threats add a layer of caution.

Q3 FY26 Earnings Season Opens with Divergent Trends

India's third-quarter earnings season for fiscal year 2026 commenced with a generally steady tone, though significant disparities in performance have quickly emerged across corporate India. Early provisional updates from leading financial institutions reveal a healthy expansion in loan books. Axis Bank, Bank of Baroda, Kotak Mahindra Bank, Bandhan Bank, and AU Small Finance Bank all reported robust growth in net advances for the December quarter.

Consumer and Real Estate Sectors Shine

The consumer and retail segments have also delivered encouraging figures. Marico and FSN E-Commerce, operator of Nykaa, have alluded to business growth rates exceeding 20 percent. Adding to the positive momentum, real estate developer Sobha announced record sales, a substantial 52 percent increase in Q3 FY26 compared to the previous year. This surge highlights strength in the property market.

Lagging Performers and Sector Headwinds

However, the narrative of uniform success does not hold for all. HDFC Bank, while showing steady loan growth, experienced a more moderate pace. Updates from consumer staples companies like Dabur India and Trent, along with retail giant Avenue Supermarts, have been less exhilarating and have broadly lagged initial estimates. IndusInd Bank reported a decline in net advances, attributed to company-specific issues.

Resilience Amidst Shifting Dynamics

Consumer staple companies demonstrated resilience, effectively navigating the transition following GST rate cuts. This involved managing inventory liquidation and dealer restocking. The passenger vehicle and two-wheeler segments also saw improved sales momentum in the December quarter, bolstered by GST adjustments and manufacturer price reductions. The pharmaceutical sector concluded 2025 positively, with domestic market sales up by 10.59 percent in December.

Cautious Optimism Amid Global Uncertainty

Looking ahead, consumer staples firms Marico and Dabur India anticipate a stable operating environment. Marico expressed optimism for gradual consumption improvement in coming quarters, citing easing inflation, enhanced affordability from lower GST rates, minimum support price (MSP) hikes for agricultural products, and favorable crop sowing seasons.

Major sectors like IT services and pharmaceuticals are still expected to report moderate performance. The financial showing for pharmaceutical companies may be tempered by slower new product launches in the U.S. market. Additionally, commodities, metals, and oil and gas companies will significantly influence overall earnings trends. Investors are also closely watching the potential impact of elevated U.S. tariffs on India's goods and merchandise exports.

Despite these complexities, the absence of major negative surprises in the quarterly updates so far offers a degree of reassurance for investors. Nevertheless, a substantial number of companies are yet to release their December quarter results.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.